Jeffrey Conroy is a Chicago-born, American-bred, and New Jersey–based biopharma strategist, oncology operator, and systems‑driven innovator. As Founder, CEO, and Fractional Chief Operating Officer (COO) of Catalyst Oncolytics Corporation, he brings a multidisciplinary background spanning clinical development analytics, distressed‑asset triage, competitive intelligence, and operational architecture across leading oncology organizations.

Conroy’s career includes leadership roles at Y‑mAbs Therapeutics (acquired by SERB - 2025), Karyopharm Therapeutics Inc., Bristol Myers Squibb, and Celgene (acquired by BMS - 2019), where he supported global oncology integration, adult and pediatric oncology commercialization, Cell Therapy strategy, and cross‑functional launch operations. Jeff has the ability to connect clinical realities, data, and business needs into coherent, patient‑centric strategic direction.

He is also the Founder & Managing Principal of New Jersey's Global HC Analytics LLC, a consultancy specializing in oncology insights, competitive intelligence, market analytics, and strategic development support for emerging and established biopharma teams.

Jeff's Healthcare and Engineering foundation was built at Northwestern University, where he earned a B.S. in Computer Engineering with coursework in digital systems design, neural networks, numerical methods, and applied physics. He later completed a Mini‑MBA in Biopharma Innovation at Rutgers University, strengthening his expertise in drug development, regulatory pathways, and commercialization frameworks.

Catalyst Oncolytics reflects Jeff's belief that Oncology Innovation requires mechanistic clarity, disciplined execution, and best in class Artificial Intelligence models - Cancer Patients cannot afford delays. Jeff is recruiting his Dream Team to help build Catalyst Oncolytics into a private high‑velocity firm positioned for meaningful clinical impact and long‑term value creation.